Gland Pharma Limited (GLAND) Earnings Call Transcript & Summary
November 6, 2026
Earnings Call Speaker Segments
Operator
operatorGood day, ladies and gentlemen, and welcome to Gland Pharma's Q2 FY '27 earnings conference call. <<operator_script>> Kindly be aware that this call is being recorded. At this point, I'll turn the conference over to Mr. Shriniwas P. Dange of the Investor Relations team. Thank you, and the floor is yours, sir.
Shriniwas Dange
executiveThanks, Swapnali. Good evening, everyone. We're glad to have you join us for Gland Pharma's Earnings Conference Call covering Q2 of FY '27. This is Shriniwas Dange speaking, from the Investor Relations team here at Gland Pharma. Joining us today are Mr. Srinivas Sadu, our Executive Chairman, and Mr. Ravi Mitra, Chief Financial Officer, both from the India Office. Mr. Sadu will kick things off with business and operational highlights, and after that Mr. Ravi will walk us through the group financial overview. Before we get going, a quick reminder that certain statements made today are forward-looking and rest on management's current estimates. Such statements ought to be viewed in light of the risks tied to our business. This call is being recorded. A playback along with the script will be posted on our website shortly. With that, I'll turn the call over to Mr. Sadu for his opening remarks. Sir, over to you.
Srinivas Sadu
executiveThank you, Shriniwas. Good evening, everyone, and a very warm welcome to each of you on Gland Pharma's earnings call covering the second quarter and first half of fiscal year 2027. I'll start with the business and strategic overview, and after that Ravi will walk you through the financial performance in more detail. We're happy to report yet another quarter of robust growth and solid execution. In Q2 FY '27, revenue came in at INR 18,336 million, which works out to 23% growth year-on-year, and EBITDA rose 53% year-on-year to INR 4,804 million. Adjusted EBITDA stood at INR 5,030 million, with margins of 27%, and profit after tax was up 58% year-on-year at INR 2,908 million. How we performed on both revenue and profitability shows the ongoing strength of our business fundamentals, a growing contribution from the CDMO business, strong demand across our critical injectable business, successful product launches, better operating leverage and disciplined execution throughout the organization. Even more importantly, we're seeing growing validation of our strategy to build Gland Pharma into a leading global supplier of sterile injectables and a strong CDMO platform. The momentum we see across customer engagements, manufacturing partnerships, capacity expansion initiatives and development programs gives us confidence in the company's long-term growth trajectory.
Srinivas Sadu
executiveOur business strength also comes through clearly in the first half results. In H1 FY '27, revenues rose 21.4% year-on-year, reaching INR 36,339 million. Adjusted EBITDA climbed to INR 10,132 million, with margins at 28%, and profit after tax was up 52% year-on-year at INR 6,077 million. What these numbers show is the expanding scale of our operations, a rising contribution from the CDMO business, and our continued emphasis on profitable growth. The CDMO business is increasingly standing out as a major growth engine for Gland Pharma and continues to rank among the most important drivers of our long-term strategy. CDMO revenues in the quarter increased 31% year-on-year to INR 8,227 million, accounting for roughly 45% of total revenues. In the first half of FY '27, CDMO revenues came in at INR 17,142 million, up 25% year-on-year and making up approximately 47% of consolidated revenues. This growth came from commercial supply under CDMO contracts signed earlier, together with new launches in this segment and revenue from development and manufacturing partnerships entered during the quarter. Globally, the market opportunity in high-quality sterile injectable outsourcing keeps getting bigger, and we are seeing strong interest from innovators and specialty pharmaceutical companies looking for dependable partners with proven regulatory and manufacturing capabilities. Technology transfer work across the various projects is moving forward as planned.
Srinivas Sadu
executiveOngoing conversations with a number of additional multinational partners only deepen our belief that this CDMO platform can scale over the long run. We keep moving forward on multiple strategic opportunities spanning complex injectables, specialty formulations, and differentiated manufacturing platforms. In the quarter, we broadened our respiratory capabilities and won manufacturing contracts covering microspheres as well as respiratory products. Our CDMO opportunity pipeline is still robust, with quality and scale better than at any prior point, giving us greater visibility and confidence regarding where growth is headed. Moving to Cenexi: we are pushing our transformation road map ahead to make the platform more competitive over time. Quarterly revenues came in at EUR 41 million, with an EBITDA loss of EUR 6 million, mainly reflecting planned annual shutdowns at the facilities. The underlying operating trend is still encouraging. Better capacity utilization, continued cost optimization, and rising operating leverage should bring profitability back starting in Q3, consistent with the positive results of earlier quarters. Our strategic objective is the same as before: to establish Cenexi as an integrated CDMO platform that provides specialty manufacturing capabilities along with a broad range of development and manufacturing solutions. Our critical injectable business kept up a strong showing in the quarter. Revenue was INR 10,109 million, up 18% year-on-year.
Srinivas Sadu
executiveLooking at H1 FY '27, revenue from this business came in at INR 1,197 million, which was also up 18% year-on-year. That growth was backed by robust demand for our current portfolio, the contribution of recent launches, ongoing customer acquisitions, and greater volumes across key products and markets. Our focus stays on reinforcing our leadership position in sterile injectables by expanding the portfolio, executing commercially, ensuring supply reliability, and building differentiated manufacturing capabilities. Now turning to how the group performed geography-wise. The United States was still our biggest market and turned in an exceptional quarter. Revenue rose 42% year-on-year to INR 11,795 million. During the first half of FY '27, U.S. revenue reached INR 21,605 million, a rise of 37% year-on-year. This growth came from the contribution of recent launches, rising volumes from existing products, and sustained momentum in our CDMO programs. Our key products, recent launches included, keep performing well in the market. In the quarter, we introduced 4 products in the U.S. market and still see further opportunities for portfolio expansion and market share gains. Revenue from Europe and other regulated markets increased 23% year-on-year to INR 4,110 million. For H1 FY '27, revenue from Europe and other regulated markets was INR 8,598 million, which reflects 17% year-on-year growth.
Srinivas Sadu
executiveCustomer engagement rose, existing products delivered larger volumes, we had recent launches, and commercial traction improved in both the CDMO and critical injectable business — all of which drove growth. We keep reinforcing where we stand in the market via differentiated products, stronger customer relationships and disciplined, focused execution. For the quarter, revenue from rest of the world markets came in at INR 2,044 million. Certain market-specific supply and tender-related dynamics weighed on performance, particularly the delay in announcement of NUPCO tender results out of Saudi Arabia. Even so, demand fundamentals in our key emerging markets are still healthy, and we keep seeing attractive opportunities for long-term growth. India revenue for the quarter was INR 387 million. India is still a comparatively small piece of our overall business, but we continue to assess selective opportunities for expanding the portfolio and developing the market. Let me now walk you through our core growth pillars. At Gland Pharma, quality and compliance stay a top priority and keep setting us apart in the global marketplace. In the quarter, our Vizag oncology facility came through a U.S. FDA inspection with 0 observations, which reflects the strength of our quality systems, operational discipline and compliance culture. Our Dundigal facility was also inspected by the U.S. FDA during October and wrapped up with 4 procedural observations.
Srinivas Sadu
executiveAlso worth noting, we had zero data integrity findings and no repeat observations. Those inspection results confirm how mature our quality systems are and strengthen the trust that customers and regulators have in Gland Pharma as a reliable manufacturing partner worldwide. We keep investing ahead of demand in manufacturing infrastructure to back our next growth phase. Utilization rates at our sites keep climbing, driven by rising demand, larger volumes and productivity efforts already underway. The INR 2,000 crore capacity expansion program we announced earlier remains on schedule, and it covers more capacity for ophthalmic products, a new BFS line, and upgraded oncology and sterile manufacturing capacity using isolator technology. We expect these investments to broaden our presence in complex, specialized product categories and to underpin future growth opportunities. Extra bag manufacturing capacity that was installed during the year is waiting on a U.S. FDA inspection, and after that we could commercialize products from this line, which would relieve the capacity constraint affecting our product supplies. Because we expect capacity constraints on certain product lines owing to the newer CDMO contracts signed recently, we are launching a brownfield expansion program at our Pashamylaram facility. Initially, this facility will contain 3 isolator-based vial manufacturing lines to meet additional volume needs.
Srinivas Sadu
executiveWe expect the total CapEx outlay to come in at roughly INR 10,000 million, and commercial operations are anticipated to begin from FY '20 onwards. We've also kicked off a greenfield project at Vizag SEZ, which should further bolster our capacity to support long-term growth across both our commercial and CDMO businesses. Land has been acquired for this purpose, and we're working on the project plan. In the coming quarter, we will seek the Board's approval for the additional CapEx toward this expansion. Research and development remains central to our growth strategy. During the quarter, we spent INR 1,077 million on R&D — that is 6% of our revenues — and have filed 11 ANDAs, received 10 approvals and launched 4 products in the U.S. Our R&D efforts continue to focus on complex injectables, differentiated technologies and specialty products where we can create sustainable competitive advantages and long-term value. We have signed a term sheet to in-license another long-acting injectable product from China. This is the second product we signed in the past 2 quarters. We are actively evaluating multiple in-licensing opportunities of complex products that can further strengthen our future product portfolio. On the human capital front, we have recently strengthened leadership across both Gland Pharma and Cenexi.
Srinivas Sadu
executiveAs we shared earlier, Gland Pharma's incoming CEO, Mr. Deepak Sapra, is set to come on board on November 16, and Mr. Ajay Sahni joined at the start of this week as President of Cenexi operations, where he'll drive the following stage of that business's transformation and growth. We've also kept making our management team stronger by adding key leaders and enhancing the organization. Over the last 1 year, we've brought in several key people across R&D and manufacturing. During the recent quarter, to carry out CDMO business contracts, we bolstered our team and brought on a new Head of Tech transfer, plus 2 senior people for project management. Beyond that, we've now onboarded a Head of Strategy and Innovative Medicines in India, as well as a business development head situated in China, whose focus is bringing innovative and specialty products from China to India. To boost our investments and M&A capability, we will be onboarding the Chief Investment Officer, located in China, to concentrate on China-based opportunities. Taken together, these steps should sharpen execution, deepen customer engagement and underpin sustainable profitability improvement over the medium term. In summary, we posted another quarter and first half of strong growth, fueled by rising momentum in our CDMO business, a solid showing from our critical injectables business, successful product launches and ongoing operational excellence.
Srinivas Sadu
executiveWe're reinforcing our manufacturing network, growing our technology capabilities, deepening relationships with customers, and putting investment behind several long-term growth platforms. The opportunities in front of us are significant. Rising global demand for sterile injectables, together with growing outsourcing trends and our differentiated capabilities, puts Gland Pharma in a strong position to create sustainable long-term value. We remain highly confident in our strategy, our execution capabilities, and the long-term growth prospects of the company. Thank you for your continued trust and support. I will now hand the call over to Ravi for the financial review. Over to you, Ravi.
Ravi Mitra
executiveThank you, Mr. Sadu. Good evening, everyone, and thanks for being with us today as we go through our financial results for the second quarter and the first half of financial year 2027. As our Executive Chairman pointed out, we posted yet another quarter of robust growth, which shows how resilient our business model is, the expanding contribution from our CDMO business and the ongoing strength of our critical injectables business. What we achieved reflects the payoff from strategic investments we have made over the past several years in manufacturing capabilities, technology platforms, product development, customer relationships and operational excellence. Importantly, we keep delivering profitable growth at the same time as we invest for the future through higher R&D spending, capacity expansion initiatives and differentiated technology capabilities. That balanced approach puts us in a good position to sustain growth and create long-term shareholder value. Consolidated revenue for the second quarter of FY '27 came in at INR 18,336 million, a rise of 23% year-on-year. This growth was fueled by strong momentum across our CDMO business and critical injectables business, backed by recent product launches, higher volumes from existing products, continued customer demand across key geographies such as U.S. and Europe and a growing contribution from strategic manufacturing partnerships. Looking at the business mix, the CDMO segment's increasing contribution keeps enhancing both the quality and the visibility of our revenue base.
Ravi Mitra
executiveFor the quarter, CDMO revenues rose 31% year-on-year to INR 8,227 million, and revenue from our critical injectables business increased 18% year-on-year to INR 10,109 million. We find the ongoing growth of the CDMO business especially encouraging, since it does more than support revenue growth — it also strengthens customer stickiness, long-term visibility and the company's overall strategic positioning. Let me also briefly cover how we performed on revenue in the first half of FY '27. We put up a strong first half, which reflects continued momentum across our businesses and successful execution of our strategic priorities. Consolidated revenues for H1 FY '27 came to INR 36,339 million, a rise of 21% year-on-year versus INR 29,925 million in the same period a year earlier. The growing share contributed by the CDMO business remains especially encouraging. In H1 FY '27, CDMO revenues climbed 25% year-on-year to INR 17,142 million, accounting for roughly 47% of consolidated revenues. The critical injectables division posted revenues of INR 1,197 million, up 18% year-on-year. Taken together, the first half shows the strength of our diversified business model, the growing contribution from higher-value opportunities and our capacity to deliver sustainable growth while we keep investing for the future. Gross margin for the quarter was 63%, and for the first half it was 64%, unchanged from the same period last year.
Ravi Mitra
executiveEven as we keep putting money into future growth opportunities, our attention to productivity gains, manufacturing optimization, alternate sourcing, and yield enhancement initiatives continues to bolster margin resilience. One notable highlight this quarter was our sustained investment in innovation and pipeline expansion. R&D expenditures rose to INR 1,077 million, which works out to 6% of revenues, versus INR 772 million in the prior quarter. Cumulative R&D expenditure for the first half of FY '27 came to INR 1,849 million, equal to 5% of revenue. During the quarter, even with that sizable jump in R&D investment, we delivered an EBITDA margin of 26%, which shows the strength of the underlying business, the benefit of operating leverage, and disciplined cost management. Our R&D investment stays concentrated on complex injectables such as suspension, peptide, hormones, and ophthalmic solutions, as well as other differentiated technology platforms capable of supporting sustainable long-term growth. Reported EBITDA for the quarter was INR 4,804 million, an EBITDA margin of 26% against approximately 21% in the corresponding quarter of the prior year. Adjusted for non-cash ESOP expense of INR 226 million, adjusted EBITDA came in at INR 5,030 million, which translates into an adjusted EBITDA margin of 27%. This substantial profitability improvement was backed by stronger revenue, growing CDMO contribution, a favorable business mix, operating leverage benefit, and ongoing efficiency initiative across our manufacturing network.
Ravi Mitra
executiveEven with a substantial increase in R&D spending, our capacity to grow margin demonstrates how strong and scalable our operating model is. For the first half, EBITDA came in at INR 9,734 million, giving an EBITDA margin of 27%. Adjusted EBITDA was INR 10,132 million, which works out to an adjusted EBITDA margin of 28%, versus adjusted EBITDA of INR 7,092 million in H1 FY '26. Other income came to INR 690 million in the second quarter and INR 1,302 million across the first half, made up mainly of interest income on our cash balance plus FX gain. Other income for Q2 FY '27 rose against the prior year, yet it fell relative to Q1 FY '27, chiefly because of a change in FX gain loss. The effective tax rate was roughly 33% for the quarter and roughly 30% for the first half. Because losses at Cenexi do not qualify for current or deferred tax benefits, the elevated tax rate stemmed mostly from greater losses at Cenexi in the quarter, which arose from planned annual summer shutdown activities. As Cenexi's operating performance strengthens and profitability comes back from Q3 onwards, we anticipate the overall effective tax rate will normalize going forward.
Ravi Mitra
executiveFor the quarter, profit after tax came in at INR 2,908 million, which works out to 58% growth year-on-year, even with the drag from significantly higher R&D investment and the temporary profitability pressure at Cenexi caused by the annual shutdown period. PAT margin for the quarter was roughly 16%. Profit after tax for H1 FY '27 was INR 6,077 million, a robust 52% increase year-on-year versus INR 3,992 million in the same period last year. PAT margin came in at 17%. This strong profitability growth reflects rising scale, better operating leverage, a growing contribution from the CDMO business, and disciplined execution throughout the organization. Our balance sheet remains strong and gives us significant flexibility to pursue both organic and inorganic growth opportunities. As of September 30, 2026, cash and cash equivalents were INR 34,412 million. Adjusting for debt, the company held a robust net cash position of approximately INR 32,216 million. This strong financial position gives us ample flexibility to support our ongoing capacity expansion initiatives, invest in differentiated technology platforms, evaluate strategic business opportunities, and pursue disciplined capital allocation priorities. Cash flow from operations in the first half of FY '27 was INR 6,027 million, reflecting strong operating performance and disciplined working capital management.
Ravi Mitra
executiveCash generation stayed at a healthy level through the period. Working capital days came down to 158 days, mainly because of inventory optimization initiatives and better inventory management practices throughout the business. Our focus continues to be on lifting working capital efficiency while keeping service levels high and supply reliable for customers in global markets. Our capital allocation framework stays disciplined and centered on creating value over the long term. As we said earlier, we are continuing to carry out our capital expenditure program, which is designed to support future growth across commercial products, CDMO partnerships and differentiated technology platforms. In the India operations, investment continues in vial capacity expansion, ophthalmic capabilities, BFS infrastructure, liposomal platforms and other specialized technologies. We are also backing future growth with additional bag manufacturing capacity, the development of advanced isolator-based capabilities for oncology and ophthalmic products, brownfield expansion plans at Pashamylaram and progress on plans for our greenfield project in Vizag SEZ. These investments are being made with capacity demand in mind and reflect how confident we are in the growth outlook across both the CDMO business and the critical injectables business. At Cenexi, the planned investment, including the new vial and lyophilization block at BLA and the high-speed ampoule line at Fontenay, remains on track and is expected to strengthen the platform's competitiveness and its potential for future growth.
Ravi Mitra
executiveNow, focusing specifically on Cenexi. For the quarter, Cenexi posted revenue of EUR 41 million — up from EUR 40 million in the prior year — along with EBITDA of roughly negative EUR 6 million. Those results mainly mirror the effect of the planned annual summer shutdowns that took place during the quarter. Once you set aside that temporary factor, the underlying business is still heading in the right direction. Work on adding capacity, cost optimization programs, efforts to engage customers and integration activities is all advancing nicely. With a stronger leadership team and an integrated customer offering, restructuring efforts that are ongoing and several business development opportunities currently under discussion, our confidence in Cenexi's trajectory and in its long-term strategic value to the group remains intact. In closing, the first half of FY '27 shows sustained momentum throughout the business, strong execution against our strategic priorities and continued progress in improving the quality of our earnings. We are growing while at the same time investing in R&D, manufacturing infrastructure, advanced technology platforms and creating future capacity. The growing contribution from the CDMO business, along with our expanding global manufacturing footprint and a strong balance sheet, further strengthens our long-term growth profile. With a net cash position of INR 32,216 million, healthy cash generation, disciplined capital allocation and multiple growth drivers in place, we remain well positioned to capitalize on future opportunities and deliver sustainable long-term value.
Ravi Mitra
executiveHaving said that, I'd now like to ask the moderator to please open up the lines so we can take some questions. Thanks.
Operator
operator<<operator_script>> We’ll take our first question from Saion Mukherjee with Nomura.
Saion Mukherjee
analystFor the first half, we’ve seen revenue growth of almost 21%, with good traction in the U.S., Europe, but other markets. And as you mentioned, there was an issue. So assuming the currency remains at the current levels, what’s the full year expectation? And how do you see the U.S. revenues? Can it sustain, improve from here and also the rest of the world, if you can guide for the full year?
Ravi Mitra
executiveOn the currency side, Saion, it's hard to forecast. However, as we said before, our full-year growth guidance is unchanged at 15% on a constant currency basis. We'll need to watch how currency rates affect that. So growth should be broad overall, as you saw this quarter across both Europe and the U.S. market, and we expect the ROW market to pick up as well.
Saion Mukherjee
analystSo you're figuring the U.S. will more or less hold steady, with nothing one-off or bulky in those revenues, and that ROW has room to get better. Is that the way you see the second half shaping up?
Ravi Mitra
executiveRight. U.S. growth this quarter came from the new product launches and the new CDMO business. That should keep going. There's no lumpiness.
Saion Mukherjee
analystAlright, and for my second question, I'd like to ask about CapEx. You referred to INR 2,000 crores of CapEx across the coming 4 years. As I understand it, this would be a brownfield facility. You also brought up greenfield capacity at Vizag, which is likewise set to come up during those same 4 years. So taking that into account, what would the total CapEx be — the expansion CapEx? And looking at capacity, how much would it grow from the current 1.7 billion unit capacity you have once all of the expansions are finished over the next 4 years?
Ravi Mitra
executiveThere are 2 parts to this, Saion. The INR 2,000 crores covers the extra lines we're putting in beyond what we'd already announced. On another brownfield project, approval came through just today for an additional building — another block we'll construct at the facility — because when it comes to the liquid vials, capacity is running out on us. Utilization there already stands at 92%. And for next year, we're expecting something like close to 102%. So we simply don't have sufficient capacity there. To satisfy the added demand on our books and the contracts we're signing, which will reach commercialization in 2 years, that capacity needs to be ready fast. We said last quarter that we'd kicked off the greenfield project, but it will take 4 years. So we have to move quickly with this brownfield project so that within 2 years we have enough capacity. So an additional INR 1,000 crores is what we'll invest in this brownfield project, where 3 additional lines will be installed, which will serve us for the contracts signed in the recent past and those we've been discussing with various customers, starting from FY '30 once commercialization happens. As for the greenfield project, we're still at the project stage.
Ravi Mitra
executiveWe haven't announced a full CapEx figure yet. We'll likely do that next quarter, but it'll be something along the lines of a program spanning 4 years.
Saion Mukherjee
analystAll right, so if I were to put all of that together, then perhaps we're looking at roughly INR 5,000 crores of CapEx across the coming 4 years, correct, counting the greenfield? That's INR 2,000 crores plus INR 1,000 crores, and if I assume a further INR 2,000 crores — would that be a fair way to size it?
Srinivas Sadu
executiveRight. If you leave that out, the greenfield project comes to roughly INR 3,000 crores. And at INR 3,000 crores, we'd likely be adding capacity of another 300 million to 400 million units.
Operator
operatorOur following question comes from Dhawal Khut with Jefferies.
Dhawal Khut
analystEarlier, we brought up bringing on a CIO in China. So what's the goal here? Is it to buy a plant over there? Or is it about firms capable of development work on complex product? Or is it mainly in-licensing of products? How should we think about this new role?
Srinivas Sadu
executiveIt's really a blend of everything you just listed. For one thing, as we've said repeatedly, our goal is to pick up something on the biologics side here in the U.S. And this individual isn't confined to sourcing assets from China — the mandate covers acquisitions worldwide — but he brings real expertise. He's spent many years working out of China too. That gives him familiarity with a range of different countries as well. He'll also be handling in-licensing of certain complex products and some technologies coming from China. So the position is global in scope, yet anchored in China, since he understands the China landscape and the technologies available there, and he has access to various markets too.
Dhawal Khut
analystAll right, so that means we’re going to have 2 people in China — senior people, and . . .
Srinivas Sadu
executiveSo that's a single business development person plus a single CIO.
Dhawal Khut
analystAll right, understood. And one further point came up when you said you'd like to bring products over from China into India. So did you mean that you want to in-license products for the Indian plants, aimed at global markets? Is that the right way to read it? Or is the focus on serving the Indian market?
Srinivas Sadu
executiveBasically, the main thought here is how we grow our operations within India. Right now, our footprint there is quite small. We're not looking to come in with generic drugs, since competing that way is extremely tough. So the plan is to bring innovative products into the Indian market. That process has already begun. A number of companies are doing this already, and we can tap into Fosun's subsidiaries plus various other firms. It's simpler and requires less capital if you concentrate just on India, particularly because the big pharma players will license products for bigger markets, and the investments involved are larger than what the Indian market needs. So we'd like to establish a base in India as well, and from there expand our business there. That, then, is the thinking behind in-licensing these innovative products.
Dhawal Khut
analystUnderstood. Just a quick question: what are the milestone and the profit share for the quarter?
Srinivas Sadu
executiveThe overall milestone comes to roughly INR 95 crores, and the profit share stands at approximately INR 202 crores — that's 11% and 5%.
Operator
operatorOur following question comes from Tushar Manudhane, who is on the line from Motilal Oswal Financial Services.
Tushar Manudhane
analystTo start with, could you shed a bit more light on those contracts for the microsphere products — what size are they, and over what period of time?
Srinivas Sadu
executiveWe've just completed a single exhibit batch for one of those projects, and 2 further ones are queued up. Yet, as you're aware, work on these projects takes a lot of time. So for the first couple of years, the revenue we receive will lean more toward tech transfer. Once that phase is behind us, though — these are royalty-based contracts that we've signed — the development effort will also happen on the manufacturing side. So 3 projects have been signed up. As a result, the revenues will come after '29 and '30.
Tushar Manudhane
analystUnderstood. Second, on U.S. growth: existing products could see competition, so could you give us more detail on which other products, beyond ones such as dalbavancin, you expect will help maintain or even generate additional growth in the U.S.?
Srinivas Sadu
executiveA few of these products launched during the last couple of quarters, so they'll be annualized. We also just announced approval for methylprednisolone suspension, a generic version of Pfizer's Medrol—that's a large product too. Plus, we have several CDMO projects set to launch, GLP-1 projects among them.
Tushar Manudhane
analystFinally, regarding Cenexi, we did see roughly 11% growth in euro terms for FY '26, though the first half was mostly flat. So how should we think about the growth prospects for Cenexi?
Srinivas Sadu
executiveAs we mentioned before with Cenexi, the emphasis is on boosting efficiency and profitability instead of the top line. Revenue-wise, growth will be minimal, but the aim is to make it more profitable. That is actually why, while the rest of the business is expanding at a quicker pace, we are holding back more on the revenue growth side at Cenexi. Still, as a consolidated company, we view 15% as growth. So the remainder of the business will expand at a quicker rate than Cenexi.
Tushar Manudhane
analystYet this business already enjoys a very high gross margin, and even so we remain at a somewhat lower level of profitability, which means that, in a sense, we'll need higher revenue in order to become more profitable. Correct me if I'm wrong.
Srinivas Sadu
executiveNo. So gross margin isn't really the right lens for examining the expenses in that area. When you look at it, the costs are quite high. That's where efficiency gains will show up. So we need to — we have a plan in place for cutting headcount. And as I mentioned, we'll also be putting money into faster lines, which should then be reflected in operational efficiencies. So it's a mix of those things, because there will be a transition period when new lines are installed — there will be some shutdown periods and so on. So revenue growth might not be all that high, but the emphasis is on how we bring our costs down.
Operator
operatorOur following question comes from Neha Manpuria at Bank of America.
Neha Manpuria
analystYou brought up that certain capacities—for some of the business—are running at capacity or very high capacity levels, and so the pressure will be in brownfield. Do you think there's a risk that you probably lose out on revenue growth...
Srinivas Sadu
executiveNeha, we can’t hear you clearly, Neha.
Neha Manpuria
analystCan you hear me at this point?
Srinivas Sadu
executiveThat's an improvement.
Neha Manpuria
analystAll right. I’ll return to you on that. I’ll return to you on that.
Srinivas Sadu
executiveSure, sure.
Operator
operatorAnd our following question comes from Sajal Kapoor, who is calling in from Antifragile Thinking.
Sajal Kapoor
analystNice work on delivering yet another solid quarter, team. Cash from operations especially has stayed really robust. I mean, operating cash flow for H1 came to INR 600 crores, which pretty much lines up with profit, and net cash today sits at roughly INR 3,200 crores to fund the CapEx we've got lined up. So my first question concerns that CapEx. Of the planned growth CapEx — INR 2,000 crores for the lines, INR 1,000 crores for brownfield, plus the revised greenfield spread across 4 years at INR 5,000 crores — how much overall is supported by take-or-pay minimum volumes or some kind of customer co-funding arrangement? Or does it rest purely on a soft demand signal from the customer? I'm just trying to wrap my head around this from our usual capital allocation mindset. I mean, do we commit CapEx ahead of demand, or only once there are signals — concrete or soft — on the demand side? That's my first question.
Srinivas Sadu
executiveBroadly speaking, our approach has been to add lines once we hit a stage of 20% idle capacity. That was our usual plan. However, given the recent ups and downs, it kind of slowed down on that. But again, we have seen there a structural shift even in the marketplace where the demand is high. And our own -- the CDMO business is growing faster than what we anticipated. And as we speak, we are actually struggling for a couple of -- whether it's ophthalmic, whether it is bags, even now liquid vials, we are struggling for capacities. So we actually were supposed to take shutdowns a couple of lines, but we are not taking because we don't have capacity to fill if we take shutdown. So that's the situation we are in. Now from a business perspective, we have signed several CDMO contracts, which we need this capacity in 2 years from now because the tech transfer time takes that much time to get approvals. So while some may have take-or-pay, some may not have take-or-pay, but we do have contracts where it's getting transferred from sites which are already commercialized. So we have a pretty good view of the volumes and the forecast what they have given and what they're selling today.
Srinivas Sadu
executiveWith all of that in mind, these investments are being made. The amounts are INR 2,000 crores and INR 1,000 crores, <<inaudible>>. However, as for the greenfield project, it's more a question of examining the overall business environment. And we need to — since the present plans mean we'll exhaust our capacities there. So an additional plan is needed in order to build that. That's the reason we're still figuring out a plan, including how much must go in at the start and then how it should be expanded. So not all of it will go into the new greenfield project at one time. Instead, as we did before, it will happen in phases. So regarding the INR 3,000 crores, I believe the contracts are in place, or at minimum the forecast for those contracts is in place.
Sajal Kapoor
analystThat's useful and quite reassuring. My second question concerns Cenexi, which remains loss-making 3 years after your acquisition of it. So ahead of purchasing a U.S. biologics business, what lessons did Cenexi provide? And going forward, what deal-size limits, if any, would you impose on any planned or potential U.S. biologics acquisition, perhaps next year or at any other time?
Srinivas Sadu
executiveNaturally, scale is a factor too. What I mean is that it depends on how ambitious we are and what kind of margin profile the company we're acquiring has. One point is that we probably wouldn't target a loss-making business or one with very low EBITDA if it means paying somewhat more — instead, we'd go for a profitable asset. That's the first thing. Second, it comes down to how many contracts exist that will be commercialized within a year or 2. And another key consideration, I think, is the team running the operation. Overall, we find that operating a U.S. plant is easier than running a European brand. So our focus is not on purchasing anything in Europe.
Sajal Kapoor
analystTurning to Cenexi, hitting last quarter's guidance of EUR 200 million at a high single-digit margin would naturally require H2 to land at roughly EUR 111 million with a pretty high 18%, 20% kind of margin — well above anything Cenexi has delivered recently. So does that guidance still hold? And if not, what's the more realistic FY '27 number as we stand today?
Operator
operatorMy apologies for cutting in, sir, but we can't hear you.
Sajal Kapoor
analystHello? Can you hear me?
Operator
operatorLadies and gentlemen, the management line has been disconnected. Please remain on the line while we reconnect them. Ladies and gentlemen, the management line is now connected. Sir, the floor is yours.
Shriniwas Dange
executiveOkay, so we had been speaking with Sajal. Sajal, have your questions been answered at this point?
Sajal Kapoor
analystJust one quick clarification I was hoping for on Cenexi. Earlier, we guided to a fiscal '27 figure of 200 million at a high single-digit margin. Based on where we are today, that means H2 would need to land at roughly $111 million, with a margin somewhere between 18% and 20%, in order for us to reach that prior guidance of a high single-digit margin overall for FY '27. Does that earlier guidance we provided in Q1 still stand? Or do we need to revise that overall FY '27 number for Cenexi?
Srinivas Sadu
executiveNormally, in this quarter, the lower figure is already accounted for and factored into the estimate. Of course, we'll stick with the earlier estimate, and that remains on track. If anything changes down the road, we'll provide an update. Right now, we're operating under the same guidance.
Operator
operatorOur following question comes from Abdulkader Puranwala, who is on the line from ICICI Securities.
Abdulkader Puranwala
analystSir, I have 3 questions. The first one concerns the current quarter and H1. So could you tell me what constant currency revenue growth was for the quarter, and also for the first half?
Srinivas Sadu
executiveAbdul, it's really quite hard to pin down exactly how much of that is constant currency. I mean, you're also aware of how exchange rates have shifted. But we're not 100% exporting, and not precisely on the invoice date. So it isn't exactly quantifiable in that way. Yet if you look at the profitability side too, most of what we import is also priced in dollars. So keeping things the same, that same logic applies as well. So rather than focusing on an exact figure, I'd say you can take guidance from how the rate has generally moved. And typically, 80% of what we do is export.
Abdulkader Puranwala
analystOkay, got it. And the second thing I wanted to ask about is your capacity as it stands now. So the long-term view on contracts and the INR 3,000 crores CapEx is pretty clear. But looking ahead to FY '28, it would really help if you could give some detail on what the growth drivers would be in each of the two segments.
Operator
operatorMy apologies for cutting in. I’m sorry if you were speaking and couldn’t be heard.
Abdulkader Puranwala
analystOkay, hold on just a second.
Srinivas Sadu
executiveCDMO growth is outpacing the regular business. In the first half, the standard business grew around 18%, if I recall correctly, while CDMO expanded at a faster clip. And going forward, I expect that segment to keep growing more quickly than the regular business as well. On growth drivers, broadly speaking, new launches will add roughly 6% to 7%, with the remainder coming from expansion of the products — the earlier products where we've signed new contracts in the U.S. and other markets. From a capacity standpoint, a few lines are, I'd say, 100% occupied, and the new lines we're adding will help relieve those capacity constraints. And the whole CapEx plan rests on current demand plus what we're going to commercialize over the next year or 2.
Abdulkader Puranwala
analystUnderstood. And sir, just one final question on R&D spending, which came in somewhat higher this quarter. Is there anything in particular you'd want to highlight for this quarter?
Srinivas Sadu
executiveNo. Honestly, the products we're putting money into are getting more and more complex. And some — as we mentioned, we're also in-licensing certain products, and with those, one product's technology will be moved over to India. So we'll be investing in that too. So overall, I think R&D spending will rise slightly over time, given the kind of products we're working on now versus what we worked on before. But even so, on margin levels, we will keep — we'll make sure they stay intact, just as they are today.
Operator
operatorAnd our next question comes from Karan Vora, who is on the line from Goldman Sachs.
Karan Vora
analystI’ll start with the U.S. business. Could you please point out how much growth the U.S. business had, leaving out Cenexi, both in this quarter and in the base?
Srinivas Sadu
executiveAll right, the base business and the U.S. business — for the U.S. alone, growth came in at almost 42%.
Karan Vora
analystRight, so essentially whether Cenexi is in there or out, the growth comes out pretty much the same.
Srinivas Sadu
executiveYeah, pretty much the same.
Karan Vora
analystAll right, I understand.
Srinivas Sadu
executiveYet that figure stands at just 37%.
Karan Vora
analystAll right, understood. So this may be a bit of a basic question, but I'm just trying to get my head around it. Now that we've begun disclosing the breakdown between CDMO and critical injectables over the last 2 quarters, what exactly is it that we book under CDMO? In other words, what type of contract goes into CDMO, and what type of arrangement goes into injectables? Could you shed some light on that?
Srinivas Sadu
executiveInjectables covers essentially every product we create and then either license out or market ourselves within India plus a handful of other territories. So in essence, these are items Gland has developed and then supplies to customers abroad. CDMO, on the other hand, refers to products belonging to other clients that they move into our facilities, or where we run a joint development effort alongside them. That means we handle a portion of the development work as well as manufacturing right here. So that is how the segment breaks down.
Karan Vora
analystRight, so the ANDAs that we own, or that are basically in our name — those fall under critical injectables, not CDMO, correct?
Srinivas Sadu
executiveRight. Anything we create flows into our own operations, whether other firms create it or we work on it jointly. So at times they handle some preliminary work, after which we carry out the complete development in our lab, then file from a plant and proceed from there. As a result, the intellectual property often sits with them. That is what the CDMO business involves.
Karan Vora
analystUnderstood. So in that scenario, would the margin on our critical injectables end up above CDMO? Could you shed some light on how the margin might break down between critical injectables and CDMO? A rough figure would work too if you'd rather not give the exact numbers.
Srinivas Sadu
executiveI'd say the margin on the CDMO business is somewhat stronger than what we see in our own business, since our own business also carries revenue from India as well as ROW. That's where margins come in lower — it isn't just the U.S. market. Our CDMO work goes mostly to the regulated markets. So margins there are better, likely 5% better — 5% to 10% better in CDMO.
Karan Vora
analystAll right, understood. And one final point to clarify — Cenexi is entirely within CDMO, correct?
Srinivas Sadu
executiveThat's right.
Karan Vora
analystAnd CDMO margin remains higher. All right.
Operator
operatorOur following question comes from Maulik at 360 ONE Capital.
Maulik Varia
analystI had a couple of questions. First off, should we expect any contribution from GLP products during this year, in FY '27?
Srinivas Sadu
executiveWe do receive certain revenue from tech transfer projects. Recently, we also signed one additional project. So many exhibit batches are underway and taking place. As a result, we will receive some milestone income along with a tech transfer fee. And perhaps certain launches will take place in Q1 or Q2 of next year.
Maulik Varia
analystAll right, is there a way for us to put a number on what that contribution would amount to? Any guidance or ballpark figures?
Srinivas Sadu
executiveNo, we haven't provided any guidance for GLP products at this point.
Maulik Varia
analystAlright. Alright, sir. And then just one quick question on the numbers. Gross margin went down from 65% to 63.5% compared with the prior quarter. Is there any explanation or detail you can give us on that?
Srinivas Sadu
executiveThe reason for that is Cenexi brings in less revenue. Cenexi's gross margin is higher.
Maulik Varia
analystAlright, I understand.
Srinivas Sadu
executiveAnd on this, you can’t compare it with the prior quarter because of the shutdown — a 1-month shutdown at Cenexi — so revenues are lower. You have to compare it with the same quarter last year, the same quarter. Last year’s quarter.
Operator
operatorDhawal Khut with Jefferies has our next follow-up question.
Dhawal Khut
analystCould you share a bit more detail on that second product we in-licensed from China? For instance, what does the commercial timeline look like? Is there a patent on it right now? And how large is the current market for the segments we're going after?
Srinivas Sadu
executiveHold on a moment. This is a $2 billion product and it’s still under patent. The timeline is going to be 3 years. So this product — unlike the first one — the first product, the one you signed last quarter, is roughly an $800 million product. That one will be moved to India, and we’ll manufacture it there. This product, though, will be manufactured entirely in China, while the clinical work and all of that will be handled by us.
Dhawal Khut
analystRight. So our role is only that of a commercial partner — is that the right way to understand it? And the API would be coming from China?
Srinivas Sadu
executiveWe'll handle the clinical trials too. The clinical work is ours to run, and we'll serve as the commercial partner. Development efforts will be carried out by them. They'll also take care of formulation development. That said, we will conduct the clinicals, and after that we'll bring it to market.
Dhawal Khut
analystSo, when you look at these 2, is there a meaningful gap in the commercial opportunity for us — is one of them notably bigger than the other?
Srinivas Sadu
executiveWhen it comes to the market — well, you're dealing with 2 entirely separate product categories, meaning distinct therapeutic areas. Still, each one is a long-acting injectable, and each remains under patent.
Dhawal Khut
analystSo the revenue potential for us is going to be substantial, and it'll be comparable between the 2 products. Is that a correct statement to make?
Srinivas Sadu
executiveIt's a bigger market. What we signed recently, compared with the earlier one—as I mentioned, that comes to $800 million—and this one is essentially a $2 billion product.
Dhawal Khut
analystAnd is there any timeline for that Saudi contract? Would it kind of restore growth in our ROW market?
Srinivas Sadu
executiveYeah. So we keep hoping each week that they'll launch the tender. We feel fairly confident about a number of products — close to 13 products that we've put bids in for. And as in the past, we've secured a number of products in that segment. So with luck, it should take place this quarter.
Operator
operatorThat will have to be the final question, ladies and gentlemen. That brings the question-and-answer portion to a close. I'll now turn the conference over to Mr. Shriniwas Dange, who will offer the closing remarks. Thank you, and the floor is yours, sir.
Shriniwas Dange
executiveThanks, everybody, for being with us today. We’re grateful that you took part in the Q&A portion of the call. Should any follow-up questions come up, please don’t hesitate to get in touch with us. We’re looking forward to speaking with you again next quarter. Thank you.
Operator
operatorAppreciate that, members of the management team. That brings us to the end of this conference on behalf of Gland Pharma. Thanks to all of you for being with us today, and at this point you're free to disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Gland Pharma Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Gland Pharma Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Gland Pharma Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.